PRINCETON, N.J., March 12, 2013 /PRNewswire/ -- Idis announced today the appointment of Suzanne Gagnon, M.D., as Chief Medical Officer. Dr. Gagnon takes on responsibility for leading global medical affairs and providing strategic medical and regulatory leadership across all business divisions. She will also oversee global quality assurance and compliance.
"We are delighted to have Suzanne join us at this exciting time in the global expansion of Idis. Successful managed access programs require alignment among all stakeholders, from R&D though commercial teams to the physicians treating patients," noted Natalie Douglas, CEO of Idis. "Suzanne brings senior leadership to our team and a unique blend of industry expertise to our customers that will help guide development and implementation of programs that balance stakeholder requirements and effectively address the needs of patients."
The addition of the CMO role and appointment of Dr. Gagnon further strengthens Idis' offering in the US and enhances the Company's ability to deliver patient-centric programs that address the access challenges faced by patients, physicians and companies around the world.
Dr. Gagnon has more than twenty years leading the medical, regulatory and safety aspects of pharmaceutical product development and has held senior management positions in both academia and in the pharmaceutical and CRO industries. Formerly CMO and Executive Vice President at ICON Clinical Research for nearly ten years, Dr. Gagnon brings with her senior level experience in medical, regulatory and clinical research operations, as well as safety and risk management expertise.
Dr. Gagnon will be based at Idis' North American headquarters in Princeton, NJ.
Idis has 25 years experience of partnering with pharmaceutical and biotechnology companies to create regulatory-compliant, ethical access to medicines for healthcare professionals and their patients with unmet medical needs. Since 1987, Idis has developed and managed access to thousands of medicines from every therapeutic category, impacting the lives of hundreds of thousands of patients in countries around the world.
Idis leverages decades of experience, regulatory insight, and a thorough understanding of local and global requirements to create access to medicines at every stage of a product's lifecycle from pre-approval to market exit, and in times of unexpected production shortages.
The company's European headquarters are located in Weybridge, United Kingdom, and North American headquarters are located in Princeton, NJ.
For more information about Idis please visit www.idispharma.com.
Contact: Christine Quern
Phone: +1 617 761 6791